A20-28z CXCR2 CAR T-cells

A20-28z CXCR2 CAR T-cells are an experimental second-generation chimeric antigen receptor (CAR) T-cell therapy designed to treat solid malignancies. The CAR construct utilizes a 20-amino acid peptide (A20), derived from the foot-and-mouth disease virus, to specifically target the integrin αvβ6, which is overexpressed in various cancers such as pancreatic, ovarian, and breast carcinomas. The signaling architecture of the CAR includes a CD28 costimulatory domain and a CD3ζ signaling domain. To overcome the challenge of poor T-cell infiltration into solid tumors, these cells are engineered to co-express the chemokine receptor CXCR2. This modification enables the CAR T-cells to home more effectively toward interleukin-8 (IL-8/CXCL8), a chemokine frequently secreted at high levels within the tumor microenvironment. Preclinical studies have demonstrated that this dual-functional approach enhances T-cell migration, tumor infiltration, and therapeutic efficacy in xenograft models of pancreatic and ovarian cancer.

Other names

αvβ6-targeting CXCR2-expressing CAR T-cellsA20-28z-CXCR2A-20-28z-CXCR2A 20-28z-CXCR2A20-28z-CXCR2 CAR T-cellsA-20-28z-CXCR2 CAR T-cellsA 20-28z-CXCR2 CAR T-cells